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ABSTRACT  19 
The characterization of 24 lactic acid bacteria (LAB) isolates from Nigerian traditional 20 
fermented dairy foods, including some cow´s intestine isolates, was conducted in order to select 21 
isolates for potential use as probiotics. LAB isolates were identified by partial sequencing the 22 
16S rRNA gene as belonging to the species Lactobacillus paracasei, Lactobacillus brevis and 23 
mainly Weissella confusa. At the end of a characterization process, 2 L. paracasei and 2 W. 24 
confusa isolates were selected, and their resistance to a simulated gastrointestinal digestion and 25 
their ability to adhere to eukaryotic cell lines was assessed. The survival to the simulated 26 
gastrointestinal passage was higher when bacterial suspensions were made in skimmed milk 27 
(2.0±0.8 log units reduction) or at the simulated gastric juice pH 3 (2.7±0.9 log units reduction) 28 
than at pH 2.0 (5.5±0.7 log units reduction). Adhesion of LAB to both intestinal and vaginal 29 
epithelial models was comparable or higher than that of the reference Lactobacillus rhamnosus 30 
GG. However, some of the isolates increased the adhesion of the pathogen Escherichia coli 31 
LMG2092 to HT-29 and HeLa monolayers. Overall, isolates L. paracasei UI14 and W. confusa 32 
UI7 are good candidates for further studying potential benefits that support their use as 33 
probiotics. This is one of the few articles reporting the characterization and the probiotic potential 34 
of Weissella, although more studies are needed in order to establish their safety for potential 35 
probiotic applications.  36 
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1. Introduction 42 
Lactic acid bacteria (LAB) are being empirically employed from ancient times for the 43 
natural bio-preservation of raw materials. The development of food technologies involves the 44 
utilisation of specific, well-identified, and characterised LAB isolates to improve the safety as 45 
well as the organoleptical, nutritional or health properties of foods, i.e this is the basis for the 46 
concept of “functional starter” (Leroy and De Vuyst, 2004). Due to the long history of use in 47 
human consumption, some genera of LAB are “Generally Recognized As Safe” (GRAS) by the 48 
United States Food and Drug Administration (FDA). Several species of these genera are also 49 
included in the list of taxonomic units proposed by the European Food Safety Authority (EFSA) 50 
for “Qualified Presumption of Safety” (QPS) status. Among LAB with QPS status, those 51 
commonly found in fermented foods are Lactococcus lactis, Streptococcus thermophilus, and 52 
several species of Lactobacillus, Leuconostoc and Pediococcus (EFSA, 2007).  53 
Some specific LAB strains are considered as probiotics, which have been defined by the 54 
WHO/FAO as “live microorganisms which when administered in adequate amounts confer a 55 
health benefit on the host” (WHO/FAO, 2006). The genera most commonly used as probiotics for 56 
oral delivery in human consumption are Bifidobacterium and Lactobacillus (Margolles et al., 57 
2009). Even if some species of these genera are GRAS or have the QPS status, the working 58 
groups of the WHO/FAO recommend a proof that a given probiotic strain is safe. To check the 59 
safety, a series of in vitro tests are required such as, among others, the determination of the 60 
antibiotic resistant patterns and the production of toxic compounds. According to the guidelines 61 
proposed by these Organisations, one of the criteria for the selection of probiotic strains is their 62 
ability to transiently colonise the human mucosa (WHO/FAO, 2006). This property could help to 63 
maintain or improve the health of the intestinal and vaginal environments and thereby the well-64 
being of the consumer (Abad and Safdar, 2009; Lee and Salminen, 2009). 65 
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In developed countries, the search for new strains with functional properties is of great 66 
interest from both health and industrial points of view. In this way, the traditional fermented 67 
foods from non-industrialised countries constitute a reservoir to search for new strains with novel 68 
functional properties (Lee et al., 2005; Mathara et al., 2004; Mohammed et al., 2009; Thapa et al., 69 
2006). From the point of view of developing countries, the study of the properties of the isolated 70 
strains could contribute to improve the safety, quality and industrial value of traditionally 71 
fermented foods and could also open the possibility of their use for different applications.  72 
In a previous work, we have reported the antimicrobial ability of isolates from Nigerian 73 
fermented foods and animal intestines against clinical pathogens strains obtained from patients 74 
with urinary tract infections (Ayeni et al., 2009). The aim of the current work was to identify and 75 
characterise these LAB and select from them some with probiotic potential through the study of 76 
their ability to survive to simulated gastrointestinal digestion, to adhere to epithelial cell lines and 77 
to inhibit the adhesion of Escherichia coli LMG2092. 78 
 79 
2. Material and methods 80 
2.1. Identification of isolates and growth conditions  81 
In this study, we used 24 LAB isolates (Table 1) from different dairy products [cheese, 82 
fermented skimmed milk (nono), whey and milk] and animal sources (cow’s large intestine) in 83 
four geographic regions of western Nigeria (Ekiti, Osun, Ondo and Oyo). They were selected 84 
from 134 initial isolates using as a criterion their ability to inhibit the growth of uropathogenic 85 
Staphylococcus aureus strain (Ayeni et al., 2009). Selected LAB were grown in MRS (Biokar 86 
Diagnostics, Beauvais, France) broth for 24 h at 37ºC and 5% CO2 in a Heracell® 240 incubator 87 
(Thermo Electron LDD GmbH, Langenselbold, Germany) and were spread on the surface of 88 
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MRS (Biokar) agar plates to check purity. A single colony was picked up to prepare new stocks 89 
(stored at -80ºC in MRS with 20% glycerol) which were identified by partially sequencing the 90 
16S rRNA gene using the Y1-Y2 primers as previously reported (around 350 bp) (Ruas-Madiedo 91 
et al., 2005). As standard procedure, LAB isolates from stocks were cultivated overnight at 37ºC, 92 
5% CO2 and used to inoculate (2%) fresh MRS media which were cultivated for 24 h under the 93 
same conditions.  94 
 95 
2.2. Production of lactic acid and volatile compounds 96 
 The production of lactic acid in the supernatants of 24 h grown LAB cultures was 97 
measured by ion-exchange HPLC using a chromatographic system composed of an Alliance 2690 98 
module injector, a Photodiode Array PDA 996 detector and the Empower software (Waters, 99 
Milford, MA, USA) under conditions previously described (Ruas-Madiedo et al., 2005). The 100 
volatile compounds were determined by means of head-space (HS) GC-MS. Samples (400 μL) of 101 
supernatants were mixed with cyclohexanone (0.36 mg/mL) as internal standard and were placed 102 
into 10-ml glass tubes sealed with rubber and metallic caps. The analysis was carried out in a 103 
6890N Agilent GC coupled with a HS automatic injector G1888 series and with a 5975B inert 104 
MS detector (Agilent Technologies Inc., Palo Alto, CA) using conditions previously reported 105 
(Salazar et al., 2009).  106 
 107 
2.3. Antibiotic resistance pattern 108 
The minimal inhibitory concentration (MIC) against several antibiotics was studied in 9 109 
isolates selected according to their origin and belonging to different species. VetMicTM Lact-I 110 
microdilution tests (SVA, Uppsala, Sweden) were used to determine the MIC to gentamicin 111 
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(concentration range tested: 0.5-256 µg/mL), kanamycin (2-1024 µg/mL), streptomycin (0.5-256 112 
µg/mL), neomycin (0.5-256 µg/mL), tetracycline (0.12-64 µg/mL), erythromycin (0.016-8 113 
µg/mL), clindamycin (0.03-16 µg/mL), and chloramphenicol (0.12-64 µg/mL). Additionally, 114 
hand-made plates were used for the following antibiotics: ampicillin (1-1024 µg/mL, Apollo 115 
Scientific Ltd., Cheshire, UK), ciprofloxacin (0.1-128 µg/mL, Sigma Chemical Co., St. Luis, 116 
MO, USA), trimethoprim – sulfamethoxazole (TMP-SMX, 0.25-256 µg/mL, Celtech Pharma 117 
S.A., Madrid, Spain), fosfomycin (3.13-3200 µg/mL, Pharmazam, Barcelona, Spain) and 118 
nitrofurantoin (0.25-256 µg/mL, Laboratorios ERN S.A., Barcelona, Spain). When necessary, the 119 
concentration of the excipient was subtracted for the calculation of the corresponding 120 
concentrations of each antibiotic. The LAB isolates were cultured overnight on agar LSM [90% 121 
Isosensitest (Oxoid) and 10% MRS, (Klare et al., 2005)]. Individual colonies were suspended in a 122 
sterile glass tube containing 5 ml sterile saline solution. The density of each saline suspension 123 
was adjusted to an OD625 nm of between 0.16 - 0.2 was obtained. The saline suspensions were then 124 
diluted 1:1000 to obtain a final concentration of about 3x105 CFU/mL, which corresponds to the 125 
McFarland standard 1. Afterwards, 100 µL of the diluted suspensions were added to each well 126 
and incubated at 37°C for 48 h. Bacterial growth was visually detected as a pellet at the bottom of 127 
the well and also using a Microplate Spectrophotometer Benchmark Plus (BioRad, Hercules, CA, 128 
USA). The MIC was defined as the lowest antibiotic concentration at which no visual growth was 129 
detected. When it was possible, the breakpoint standard of the FEEDAP panel (EFSA, 2008) was 130 
used.  131 
 132 
2.4. Probiotic selection criteria 133 
2.4.1. Survival to the gastrointestinal transit 134 
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 The survival to the chemically simulated gastrointestinal (GIT) transit was studied for 4 135 
LAB, previously selected base on their antibiotic susceptibility profile, their antagonistic activity 136 
towards pathogens and their antimicrobial metabolite production (see supplementary material). 137 
The GIT transit simulation was performed using the procedure described by Sánchez and co-138 
workers (2010). In brief, 24-h MRS grown cultures (around 7 log CFU/ml for Weissella and 9 log 139 
CFU/ml for Lactobacillus) were washed twice in saline solution and resuspended in 140 
gastrointestinal juice (GJ: 125 mM NaCl, 7 mM KCl, 45 mM NaHCO3 and 0.3% pepsin) at 141 
different pH: 2.0, 3.0 and 2.0 containing 10% skim-milk (Difco®, Becton Dickinson, Franklin 142 
Lakes, NJ, USA). After 90 min incubation at 37ºC in aerobic conditions, bacterial suspensions 143 
were centrifuged, resuspended in duodenal juice (DJ: 1% bovine bile, pH 8.0) and incubated for 144 
10 min at 37ºC in an anaerobic chamber (10% H2, 10% CO2 and 80% N2). In the final step, 145 
bacterial suspensions were collected and resuspended in intestinal juice [IJ: 0.3% bovine bile 146 
(Sigma), 0.1% porcine pancreatin (Sigma), pH 8.0] and incubated for 180 min under anaerobic 147 
conditions previously indicated. Experiments were carried out in triplicate and in all steps viable 148 
counts were obtained by plating in MRS agar. The final percentage of survival was calculated 149 
from the ratio: CFU recovered bacteria after complete GIT challenge / CFU initial bacteria. For 150 
counting, serial dilutions in Ringer (Merck, Darmstadt, Germany) solution were made and they 151 
were pour-plated on MRS agar which was incubated for 48 h at 37ºC, 5% CO2. 152 
 153 
2.4.2. Adhesion to epithelial intestinal and vaginal cell lines 154 
Three epithelial intestinal cell lines, Caco-2, HT-29 and HT-29-MTX, the last one kindly 155 
supplied by Dr. T. Lesuffleur (Lesuffleur et al., 1990), as well as the epithelial vaginal cell line 156 
HeLa were used to assess the adhesion ability of the 4 selected bacteria. The culture and 157 
maintenance of the cell lines were carried out following standard procedures (Sánchez et al., 158 
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2010) using DMEM medium for Caco-2, HT-29-MTX and HeLa, and McCoy´s medium for HT-159 
29. All media were supplemented with 10% foetal serum bovine and with a mixture of antibiotics 160 
(50 μg/mL penicillin, 50 μg/mL streptomycin, 50 μg/mL gentamicin and 1.25 μg/mL 161 
amphotericin B). Media and reagents were purchased from Sigma. The cell lines were used after 162 
reached the confluent differentiated stay (13±1 days). The strain Lactobacillus rhamnosus 163 
LMG18243 (also named GG) was used as positive control of well-recognised adherent LAB. 164 
Cultures of the five LAB, grown overnight in 10 ml MRS under standard conditions, were 165 
centrifuged, washed twice in Dulbecco´s PBS solution (Sigma) and resuspended in DMEM or 166 
McCoy´s media without antibiotics at a concentration of about 108 CFU/mL. Cell line 167 
monolayers were also washed twice in Dulbecco´s PBS, to remove antibiotics, and bacterial 168 
suspensions (108 CFU/ml) were added at a ratio bacteria: eukaryotic cell of 10:1. Plates were 169 
incubated for 1 h at 37°C, 5% CO2 and, afterwards, wells were gently washed three times with 170 
Dulbecco’s PBS buffer to remove the non-adhered bacteria. Then, monolayers were trypsinized 171 
with EDTA-trypsine solution (Sigma) and bacterial counts were carried out in MRS agar. 172 
Adhesion results were expressed as the percentage of bacteria adhered with respect to the amount 173 
of bacteria added (% CFU bacteria adhered / CFU bacteria added). Two replicated experiments 174 
were carried out for each isolate using two independent microplates (each isolate tested by 175 
duplicate in each plate). 176 
 177 
2.4.3.  Competitive exclusion of  Escherichia coli adhesion to epithelial cell lines by probiotics 178 
The ability of the 4 selected LAB isolates to in vitro compete with E. coli LMG2092 to 179 
adhere to intestinal and vaginal epithelia, was tested using the cell lines HT-29 and HeLa, 180 
respectively (Collado et al., 2007). LAB were grown for 24 h in MRS, as previously described, 181 
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and E. coli LMG2092 was cultured overnight in LB medium at 37ºC under rigorous shaking. 182 
Bacterial cultures were washed with Dulbecco´s PBS and resuspended in the corresponding cell 183 
line media without antibiotics at concentration about 108 CFU/mL. Afterwards 500 μL of each 184 
LAB were mixed with the same volume of E. coli (ratio LAB: E. coli about 1:1) and added to 185 
each cell line type (ratio bacteria: eukaryotic cell about 10:1). Incubation took place for 1 h at 186 
37ºC in at atmosphere containing  5% CO2 (v/v). Subsequently, counts of E. coli were made in 187 
agar-LB containing 5 μg/mL erythromycin (24 h of incubation at 37ºC, 5% CO2). This 188 
erythromycin concentration was higher than the MIC detected in the four LAB isolates selected 189 
(Table 2) and checked experimentally. E. coli adhesion results were expressed as the percentage 190 
of E. coli adhered with respect to the amount added. The adhesion percentage of strain LMG2092 191 
in the absence of LAB was also tested. Two replicated experiments were carried out for each 192 
isolate using two independent microplates (each isolate tested by duplicate in each plate). 193 
 194 
2.5. Statistical analysis 195 
Data of GIT challenge and bacteria adhesion were statistically analysed using the SPSS 196 
11.0 software for Windows (SPSS Inc., Chicago IL, USA) by mean of independent one-way 197 
ANOVA tests. For bacterial GIT-resistance, the differences were tested at the final step after the 198 
sequential GIT challenge, using as factor “gastric juice type” with three categories “pH 2.0, pH 199 
3.0 and pH 2.0+skim-milk”. For LAB adhesion, the factor was “LAB type” with five categories 200 
“UI6, UI7, UI14, UI22 and GG”. For E. coli adhesion, the factor was “Bacteria type” with five 201 
categories “UI6, UI7, UI14, UI22 and LMG2092”. In all cases, the mean comparison LSD (least-202 
significant difference, p<0.05) test was used to assess differences among categories of each 203 
factor.  204 
 205 
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3. Results  206 
3.1. Identification and characterisation of LAB 207 
The 24 isolates from dairy sources (whey, milk, nono and cheese) and cow´s intestine 208 
were identified at species level by partially sequencing the 16S rRNA gene (Table 1). Most of the 209 
isolates belonged to the species Weissella confusa (71%) followed by Lactobacillus paracasei 210 
(21%) and Lactobacillus brevis (8%). The growth characteristics of the isolates in MRS broth 211 
(supplementary material table 1) varied amongst the different isolates. Table 1 shows that lactic 212 
acid was the major organic acid produced by these bacteria during growth, ranging from 13 to 21 213 
mg/mL depending on the isolate, being slightly higher in those of the L. paracasei species. The 214 
volatile compounds profile found in the supernatants of 24 h cultures was also representative of 215 
each species (Table 1). Thus, W. confusa and L. brevis produced similar levels of ethanol (higher 216 
than 3 mg/mL) and acetaldehyde, varying accordingly to isolate. In contrast, L. paracasei 217 
cultures produced very low amounts of ethanol (ranging from 10 - 26 μg/mL) and, in general, 218 
they synthesised higher amount of acetone and lower level of acetaldehyde than the other two 219 
species. To select isolates for further analyses of their probiotic potential, other parameters such 220 
as production of H2O2 and bacteriocin-like metabolites, as well as antimicrobial activity against 221 
five entero-pathogens (supplementary material tables 1 and 2) were also investigated for the 24 222 
LAB isolates. The presence of genes involved in the synthesis of biogenic amines was used as 223 
exclusion criterion and the capability to grow in milk was considered as a positive technological 224 
characteristic for potential strain delivery in dairy products. Nine isolates were selected on the 225 
basis of their origin and species identification, as well as their technological, antimicrobial and 226 
safety performance. The isolates L. paracasei UI14 and UI22, L. brevis UI3 and UI12, and W. 227 
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confusa UI4, UI6, UI7, UI18 and UI21 were chosen for further characterisation of their antibiotic 228 
resistance profiles. 229 
 230 
3.2. Resistance to antibiotics profile 231 
Table 2 shows the MICs of the 9 selected LAB isolates. In general, lactobacilli did not 232 
display high resistance levels to aminoglycosides (gentamicin, kanamycin, streptomycin and 233 
neomycin), erythromycin, clindamycin and ampicillin. On the contrary, resistance to tetracycline 234 
in L. brevis, in L. brevis and L. paracasei were close the suggested breakpoints for these species 235 
and that of chloramphenicol for some strains was even above (EFSA, 2008). Regarding W. 236 
confusa isolates, we can point out the extraordinarily high sensitivity of W. confusa UI6 to 237 
aminoglycoside antibiotics, in comparison to the other four isolates. In contrast to L. paracasei 238 
and L. brevis, all W. confusa isolates were resistant to TMP-SMX (MIC > 256 μg/mL). Finally, 239 
all the isolates tested from both genera were highly resistant to fosfomycin and nitrofurantoin. In 240 
this step, a final selection was done in which L. brevis isolates were excluded due to the presence 241 
of tetracycline resistance, in addition to the presence of genes codifying biogenic amines 242 
(supplementary material table 1). W. confusa UI4, UI18 and UI21 were not included in the final 243 
selection due to their kanamycin, streptomycin and/or neomycin resistance (Table 2). Thus, 244 
isolates L. paracasei UI14 and UI22, as well as W. confusa UI6 and UI7 were selected for further 245 
study their probiotic potential.  246 
 247 
3.3. Survival to simulated gastrointestinal transit 248 
If a putative probiotic strain is intended for oral delivery, it should survive the adverse 249 
conditions of the upper GIT tract to arrive alive to the target action site, the small and large 250 
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intestine. The viability losses of the 4 selected L. paracasei and W. confusa isolates along the 251 
different steps of the simulated GIT transit is depicted in Fig. 1. All isolates were sensitive to the 252 
simulated GJ pH 2.0, with viability losses up to 6 log units. In all cases, the addition of 10% 253 
skimmed milk to GJ pH 2.0 (which raised the pH near 4.0), or the use of GJ pH 3.0 attenuated 254 
these decreases in the viability and, besides, differences in simulated DJ (containing 1% w/v 255 
bovine bile) became apparent; W. confusa UI7 and L. paracasei UI14 resisted better the high bile 256 
salt concentration, showing lower viability decreases than the other two isolates. The final 257 
challenge to the IJ (containing 0.3% bovine bile and pancreatin) did not affect the viability of 258 
isolates. Overall, viability decrease (respect to the initial values) was improved for all isolates if 259 
the initial pH of GJ was adjusted to 3.0 or the GJ pH 2.0 was supplemented with 10% skim milk 260 
whereas, survival percentages of isolates under pH 2.0 challenge were lower than 0.003%. In 261 
addition, the statistical analysis of bacterial survival after exposure to sequential GIT transit 262 
simulation (Table 3), showed that the highest survival percentages (p <0.05) were those of 263 
isolates W. confusa UI7 and L. paracasei UI14.   264 
 265 
3.4. Adhesion to epithelial cell lines and pathogen inhibition 266 
One of the methods for estimating the ability of probiotics to transiently colonize the 267 
human mucosa is the in vitro quantification of the adhesion capability to representative cell lines. 268 
In our case, the adhesion of the 4 selected isolates to the epithelial intestinal cell lines Caco-2, 269 
HT-29 and HT-29-MTX, as well as to the epithelial vaginal cell line HeLa was evaluated (Fig. 2). 270 
Overall, adhesion of the four selected isolates to Caco-2 and HT-29 cell monolayers was poor if 271 
compared with the positive control L. rhamnosus GG. Adhesion percentages were better when 272 
HT-29-MTX was used as matrix, being in some cases even better than that of L. rhamnosus GG 273 
(isolates W. confusa UI7 and L. paracasei UI14, p< 0.05). In addition, L. paracasei isolates, 274 
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especially UI14, showed similar or better adhesion than strain L. rhamnosus GG to HeLa cell 275 
monolayers, whereas the adhesion of the Weisella isolates to this cell line was lower. 276 
Finally, the ability of the 4 LAB isolates to competitively inhibit the adhesion of E. coli 277 
LMG2092 to HT-29 or HeLa cell monolayers was also estimated (Fig. 3). In general, none of the 278 
LAB isolates inhibited the adhesion of the pathogen to both epithelial cell lines; even in some 279 
cases the opposite effect was detected. For the vaginal HeLa cell line, the isolate L. paracasei 280 
UI22 clearly favoured the adhesion of the pathogen, whereas the other three isolates increased the 281 
E. coli adherence to the intestinal cell line HT-29. 282 
 283 
4. Discussion  284 
In the present study, 24 LAB isolates from Nigerian dairy products and cow´s intestine 285 
were studied and, after a selection process, the probiotic potential of two L. paracasei and two W. 286 
confusa isolates was assessed. The most abundant isolates, identified by partial 16S rDNA gene 287 
sequencing, belonged to the genus Weissella, which is frequently isolated from different 288 
traditional fermented foods (Lee et al., 2005; Scheirlinck et al., 2007; Thapa et al., 2006) and, 289 
specifically, the species W. confusa is present in some fermented vegetables and milk (Björkroth 290 
et al., 2002), as well as in human faeces of healthy individuals (Walter et al., 2001). Weissella 291 
species are also common inhabitants of the vaginal microbiota (Jin et al., 2007; Silvester and 292 
Dicks, 2003) and even a strain of Weissella kimchii has been proposed as probiotic to prevent 293 
vaginal infections (Lee, 2005). However, the safety of this genus has not been deeply studied, and 294 
thereby, its application as probiotic should be taken carefully. Two species of Lactobacillus were 295 
identified in this study, L. paracasei and L. brevis. This genus is naturally associated with a large 296 
variety of nutritive-rich plant and animal environments and from these origins it can be present as 297 
contaminant in the raw materials used for traditional food fermentations, such as milk, meat, 298 
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vegetables and cereals (Margolles et al., 2009). In addition, several species of this genus, 299 
including L. brevis and L. paracasei, are included in the list of taxonomic units proposed by the 300 
EFSA for QPS status (EFSA, 2007). That is, based in the current knowledge available, they are 301 
safe for human consumption and, in fact, L. paracasei is present in many commercial probiotic 302 
dairy foods (Gueimonde et al., 2004). Nevertheless, the safety assessment of every strain should 303 
be checked for food use (WHO/FAO, 2006). 304 
After the first step of a rational selection process, the antibiotic resistance profiles were 305 
obtained for a subset of 9 isolates. It has been reported that resistance of LAB to antibiotics is 306 
more pronounced in sub-Sahara Africa than in other parts of the world because of the 307 
indiscriminate use of antibiotics both in human and animals (Olukoya et al., 1993). In these 308 
circumstances it is extremely important to know and characterize the resistance to antibiotics in 309 
strains potentially intended for food and/or therapeutic applications. The MIC against several 310 
antibiotics of the selected LAB showed that, in general, the Lactobacillus isolates did not display 311 
high resistance levels to most antibiotics. However, the high resistance to tetracycline in L. brevis 312 
and to chloramphenicol in L. brevis and L. paracasei suggested that specific antibiotic resistance 313 
genes could be responsible for the resistance phenotype to these two antibiotics (EFSA, 2008; 314 
Huys et al, 2008).  This implies that the presence of transferable resistance genes should be 315 
experimentally analysed as the basis for the resistance, before potential food applications of these 316 
strains. All isolates tested were highly resistant to nitrofurantoin. In this regard, high resistance 317 
levels to this antibiotic have been previously reported in lactobacilli (Charteris, 1998). In relation 318 
to W. confusa isolates, data on antibiotic resistance profiles are much scarcer. There are no 319 
defined breakpoints and just a few studies have dealt with this point (Ouoba et al., 2008; Vay et 320 
al., 2007). In spite of that, it is important to point out the high sensitivity of W. confusa UI6 to 321 
aminoglycosides, which is likely due to an increased intake of the antibiotic by the bacteria, or to 322 
 15
a facilitated binding to the ribosome. A similar phenotype has been reported in other LAB 323 
(Korhonenen al., 2008). Regarding chloramphenicol, resistance levels were similar to those found 324 
for lactobacilli. Although there are no defined breakpoints for this genus, this result could 325 
indicate the presence of specific chloramphenicol resistance genes in Weissella, which deserves 326 
future studies before application of these isolates in foods. Interestingly, and in contrast to L. 327 
paracasei and L. brevis, all W. confusa isolates were resistant to TMP-SMX (MIC > 256 μg/mL). 328 
This fact seems to be quite common in Weissella species (Liu et al., 2009) and could indicate that 329 
microorganisms of this genus posses an intrinsic resistance to antibiotics that inhibit 330 
tetrahydrofolate biosynthesis. Finally, the high resistance levels to fosfomycin detected in the 331 
three species were similar to that previously described in some other Gram-positive bacteria 332 
(Arca et al., 1997). Weissella species are common inhabitants of the vaginal microbiota and 333 
TMP-SMX is used as one of the main therapies for genitourinary tract infections (David et al., 334 
2005). Thus, the W. confusa isolates characterized in this work could be used to balance the 335 
normal vaginal microbiota during or after antibiotic treatments. It is controversial whether strains 336 
of W. confusa could be used as human probiotics for oral delivery in foods, since in spite of being 337 
detected in human faeces (Walker et al., 2001), it is not clear the relevance of this genus in the 338 
complex microbiota community or its interaction with the host. Additionally, safety is another 339 
issue that needs to be addressed before the proposal of Weissella as probiotic for human use. 340 
Although, it is worth mentioning that this genus was defined around 1990, including previous 341 
species Leuconostoc paramesenteroides, Lactobacillus confusus, Lactobacillus halotolerans, 342 
Lactobacillus kandleri, Lactobacillus minor and Lactobacillus viridescens, and (at that decade) a 343 
novel species Weissella hellenica, and that members of current Weissella genus have been 344 
consumed by humans from a variety of traditional fermented products (Bjorkroth et al., 2002).  345 
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Five out of the 9 selected isolates were excluded due to their antibiotic profiles and the 346 
other 4 were selected for their probiotic characterization using some of the in vitro tests proposed 347 
by the WHO/FAO Organizations (WHO/FAO, 2006). One of the criteria for the selection of a 348 
given strain as probiotic is its ability to survival to the stressing conditions of the human GIT 349 
tract, mainly low pH in the stomach and bile salts in the small intestine (Sánchez et al., 2008). 350 
The acidic pH stress conferred by the GJ, affected the viability of the 4 selected isolates in a 351 
lesser extent at pH 3 or if skimmed milk (10 % w/v) was included in the formulation. This fact 352 
evidenced both the high intrinsic sensibility of the isolates to low pH and the protective effect of 353 
skimmed milk, and agrees with our previous findings with Bifidobacterium animalis subsp. lactis 354 
(Sánchez et al., 2010). Surprisingly, intrinsic resistance of the selected isolates to bile was better 355 
than expected, and in fact moderate viability losses at the end of the simulated GIT digestion 356 
were detected for L. paracasei UI14 and W. confusa UI7 with an initial GJ adjusted to pH 3, or 357 
with a GJ adjusted to pH 2 in the presence of skimmed milk. It is thought that a good survival to 358 
bile may reflect also a good resistance of the probiotic to the adverse conditions of the human 359 
GIT tract (Watson et al., 2008). For this reason, the selected isolates could be proposed for oral 360 
delivery if a probiotic effect is demonstrated. In this regard, oral delivery is a convenient method 361 
for both intestinal and vaginal probiotic targets. It has been proved that orally ingested probiotics, 362 
in combination with antibiotic therapy, could restore the normal microbiota of the vagina since 363 
this niche is re-colonised with the rectal microbiota (Anukam et al., 2006; Ozkinay et al., 2005).  364 
Another criterion for selection of LAB recommended by the WHO/FAO guideline is their 365 
ability to transiently colonise the human GIT or vaginal mucosa (WHO/FAO, 2006). Usually, the 366 
adhesion capabilities of a given strain are studied using epithelial cell line monolayers, being 367 
Caco-2, HT-29 and HeLa among the most used cell lines (Vélez et al., 2007). In the present 368 
study, we have used L. rhamnosus GG, a probiotic bacterium that is commonly used as positive 369 
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control for adhesion (Tuomola and Salminen, 1998). In general, and in comparison with the 370 
adhesion values obtained for the GG strain, the selected isolates presented lower adhesion to 371 
Caco-2 and HT-29 cell monolayers, whereas its adhesion to HT-29-MTX was similar or higher. 372 
The last one is a mucin-producing colonocyte-like cell line and it has been reported that many 373 
LAB and bifidobacteria are able to stick this protective layer covering the intestinal mucosa 374 
(Collado el al., 2007; Ruas-Madiedo et al., 2006). Similarly, L. paracasei isolates showed a 375 
comparable or significantly better adherence to the vaginal HeLa cell line than strain GG. In 376 
certain situations, LAB may form a biofilm on mucosa surfaces which could confer a physical 377 
barrier for non-desirable microorganisms (Antonio et al., 2005). Globally, the good adhesion of 378 
the selected isolates, mainly L. paracasei UI14, to both vaginal and intestinal epithelia supports 379 
their potential use in both anatomic locations if a probiotic effect is shown. 380 
In certain situations, opportunistic pathogens invade the human mucosa due to a decrease 381 
in the number of protective bacteria. In this sense, exogenous probiotic administration may 382 
inhibit pathogen adhesion by competitively blocking common receptor molecules. In addition, 383 
some probiotics have antimicrobial capability which is normally due to the production of several 384 
primary and secondary metabolites, such as organic acids (mainly lactic acid), carbon dioxide, 385 
volatile compounds (ethanol, diacetyl), hydrogen peroxide and bacteriocins, among other factors 386 
(Rouse and van Sinderen, 2008). Most isolates tested in this study increased the adhesion of the 387 
pathogen E. coli LMG2092 to HT-29, as well as the isolate L. paracasei UI22 to HeLa cell 388 
monolayers. This fact has been previously observed for some commercial probiotic strains 389 
(Collado et al., 2007), as well as for lactobacilli and bifidobacteria from different origins 390 
(Gueimonde et al., 2006; Ruas-Madiedo, 2006). Our results suggest that some LAB, seen as 391 
receptor structures, might immobilize the pathogens thus blocking their adhesion to the 392 
eukaryotic cells. This hypothesis needs to be demonstrated, but it has been proposed that the 393 
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formation of such a ternary complexes eukaryotic cell-LAB-pathogen could be able to confer an 394 
antimicrobial effect since as far as LAB and pathogens stay in a close contact, the effect of 395 
potential antimicrobials could be magnified (Boris and Barbés, 2000; Osset et al., 2001). 396 
Moreover, it has been reported that a direct contact between probiotics and pathogens can 397 
decrease the cell division rate of the latter (Coudeyras et al., 2009). In any case, the relevance of 398 
the increase of E. coli adhesion to cell lines in presence of some of our LAB isolates deserves 399 
further investigations.  400 
 401 
Summarising, in the present study we have characterized 24 LAB and 4 of them were 402 
further selected to in vitro evaluate their use as potential probiotics. In general, the isolates 403 
showed good survival to the GIT transit and acceptable adhesion capability to intestinal and 404 
vaginal epithelia when compared to their respective positive controls. L. paracasei isolates were 405 
able to grow and acidify milk thus indicating good technological properties for the manufacture 406 
of dairy fermented foods. Besides, L. paracasei species has the QPS status whereas Weissella 407 
genus, which has been studied in less extent, for the moment was not included in the EFSA list. 408 
Although this study aimed a preliminary characterization of the probiotic potential of the 4 409 
selected strains, we could suggest that UI7 isolated, showing slightly better adhesion than the rest 410 
of isolates to intestinal cell lines, could be most suitable for a potential application in the gut 411 
ecosystem. For vaginal applications, UI14 could be the most interesting isolate. However, more 412 
studies are needed mainly concerning safety aspects, and health benefit properties before the 413 
application of these isolates to the formulation of functional probiotics intended for oral or 414 
vaginal delivery. 415 
 416 
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Table 1 572 
Origin of LAB isolates from different traditional fermented dairy products and cow´s intestine1.  573 
     Mean ± SD 
     mg/mL    μg/mL  mg/mL 
Species Isolate Origin Region  Lactic acid   Acetaldehyde  Acetone   Ethanol  
L. paracasei UI1 Whey Oyo  21.77±2.93  13.32±0.20 36.21±5.73  0.012±0.003 
 UI2 Whey Oyo  20.26±0.97  15.77±3.04 34.66±4.75  0.026±0.013 
 UI9 Whey Osun  19.74±0.88  12.99±2.94 32.06±4.45  0.024±0.015 
 UI14 Whey Oyo  19.68±0.71  12.77±2.43 38.06±5.54  0.019±0.006 
 UI22 Whey Ekiti  18.07±4.36  12.56±2.78 27.22±7.97  0.010±0.003 
L. brevis UI3 Whey Oyo  16.54±3.45  42.43±9.11 3.99±0.14  3.27±1.22 
 UI12 Cow intestine Ekiti  13.70±3.80  24.87±2.42 7.48±4.57  4.29±0.37 
W. confusa UI4 Whey Oyo  13.22±2.04  51.84±5.86 28.09±4.09  4.03±0.24 
 UI5 Cow intestine Oyo  13.39±1.02  46.73±7.02 23.88±3.73  3.81±0.28 
 UI6 Cow intestine Oyo  14.81±1.94  49.72±7.65 23.65±4.88  3.47±1.57 
 UI7 Cheese Oyo  13.61±1.78  45.71±10.06 23.07±0.42  3.78±0.12 
 UI8 Whey Ekiti  15.39±3.57  49.58±13.39 24.63±1.30  4.01±0.46 
 UI10 Nono Ondo  15.93±3.22  39.32±8.93 26.59±8.27  2.68±1.32 
 UI11 Whey Osun  13.37±1.32  56.56±12.06 30.33±4.86  4.82±0.61 
 UI13 Whey Ekiti  14.43±2.05  54.78±14.00 30.38±4.20  4.70±0.54 
 UI15 Cow intestine Oyo  14.14±2.17  39.07±6.23 28.30±1.55  3.96±0.21 
 UI16 Milk Ekiti  13.93±2.30  64.02±25.49 32.75±16.83  5.03±1.81 
 UI17 Cow intestine Oyo  15.00±2.73  49.95±14.15 26.49±1.32  4.13±0.50 
 UI18 Cheese Osun  14.26±2.28  46.76±14.35 24.81±4.55  4.00±0.54 
 UI19 Cow intestine Oyo  14.26±1.97  45.88±10.11 22.25±2.02  3.89±0.26 
 UI20 Cow intestine Oyo  15.01±2.32  44.92±9.08 16.91±1.14  4.07±0.16 
 UI21 Milk Ekiti  13.73±2.10  47.01±6.75 19.70±5.81  3.81±0.50 
 UI23 Nono Ondo  13.59±1.38  35.05±16.78 15.80±7.76  3.94±0.54 
 UI24 Cow intestine Oyo  14.14±2.49  55.90±15.70 21.17±0.50  4.91±0.83 
1. Production of metabolites (lactic acid, acetaldehyde, acetone and ethanol) in MRS broth after 24 h of cultivation.  574 
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Table 2 575 
Minimum inhibitory concentration (MIC) against antibiotics of selected LAB isolates from different sources.   576 
  MIC (μg/mL) 
Bacteria Isolate GEN KAN STR NEO TET ERY CLI CHL AMP CIP TMP-
SMX 
FOF NIT 
L. paracasei UI14 2 128 32 16 1 0.12 0.06 8 4 2 16 >3200 256 
 UI22 2 32 32 4 1 0.12 0.06 4 4 2 8 >3200 256 
L. brevis UI3 <0.5 8 8 <0.5 16 0.12 0.25 4 4 8 2 >3200 >256 
 UI12 <0.5 8 8 <0.5 16 0.12 0.25 8 4 8 4 >3200 >256 
W. confusa UI4 2 64 32 2 4 0.25 0.5 16 2 2 >256 >3200 >256 
 UI6 <0.5 <0.2 1 <0.5 4 0.12 0.5 16 <1 <2 >256 >3200 >256 
 UI7 8 128 64 8 8 0.25 0.06 8 8 4 >256 >3200 >256 
 UI18 4 128 32 >256 4 0.5 0.12 8 4 2 >256 >3200 >256 
 UI21 2 32 16 5 4 0.25 0.12 4 4 8 >256 >3200 >256 
 577 
GEN: gentamicin, KAN: kanamycin, STR: streptomycin, NEO: neomycin, TET: tetracycline, ERY: erythromycin, CLI: clindamycin, CHL: 578 
chloranphenicol, AMP: ampicillin, CIP: ciprofloxacin, TMP-SMX: trimethoprim – sulfamethoxazole, FOF: fosfomycin, and NIT: nitrofurantoin.   579 
 580 
 581 
  582 
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Table 3 583 
Percentage of survival after the chemically simulated gastrointestinal transit. 584 
 585 
  Mean ± SD 2 
Sample 1  Isolates % survival 3 
pH 2.0 + 10% milk W. confusa 
 
L. paracasei 
UI6 
UI7 
UI14 
UI22 
1.04±0.62 a 
4.13±0.87 b 
1.39±0.86 a 
0.19±0.14 a 
** 
pH 3.0 W. confusa 
 
L. paracasei 
UI6 
UI7 
UI14 
UI22 
0.03±0.02 a 
2.11±0.11 c 
1.22±0.88 b 
0.04±0.01 a 
** 
1. The survival percentage for sample pH 2.0 was lower than 0.003% for all isolates.  586 
2. CFU /mL recovered with respect to the initial number of bacteria 587 
3. Values within each sample not sharing a common letter are significantly different (p<0.05) 588 
according to the LSD (least significant difference) mean comparison test. 589 
** One-way ANOVA p<0.01 590 
  591 
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FIGURE LEGEND  592 
Figure 1: Counts (Log CFU/mL) of four isolates of Weissella confusa and Lactobacillus 593 
paracasei after the chemically simulated gastrointestinal transit. GJ: gastric juice (pH 2.0 594 
black circles, pH 2.0 + 10% skim-milk white circles, and pH 3.0 black triangles), DJ: 595 
duodenal juice and IJ: intestinal juice. The coefficient of variation (standard 596 
deviation*100/mean) of these results varied ranged among 1% to 12 %.  597 
 598 
Figure 2: Percentage of adhesion (CFU/mL of adhered bacteria respect to CFU/mL of added 599 
bacteria) of four isolates of Weissella confusa and Lactobacillus paracasei to the intestinal 600 
epithelial lines Caco2, HT29 and HT29-MTX and to the vaginal epithelial line HeLa. Whiting 601 
each cell line, columns that do not share the same letter are statistically different according to 602 
the LSD (least significant differences) mean comparison test (p< 0.05). Lactobacillus 603 
rhamnosus GG was used as reference strain.  604 
 605 
Figure 3: Inhibition of Escherichia coli LMG2092 adhesion to the intestinal epithelial line 606 
HT29 and to the vaginal epithelial line HeLa, in presence (and absence) of four isolates of 607 
Weissella confusa and Lactobacillus paracasei. The percentage of E. coli adhesion was 608 
calculated as follows: CFU/mL of adhered E. coli respect to CFU/mL of added E. coli. Within 609 
each cell line, columns that do not share the same letter are statistically different according to 610 
the LSD (least significant differences) mean comparison test (p< 0.05). 611 
  612 
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Figure 1 613 
 614 
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Figure 2 617 
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Figure 3 621 
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